pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Gene Therapy (AAV) · news · pharmadog
← back to Gene Therapy (AAV)
News · Gene Therapy (AAV)
527
stories
24d
Australia's clinical trial advantage gains ground amid U.S. uncertainty
biospace
26d
Alnylam plans pivotal trial as Huntington’s drug notches ‘best-in-class knockdown’
biospace
26d
BMS sheds light on patient death in CAR-T trial, wants to get program back on track
fiercebiotech
26d
US explores China biotech restrictions, exempts licensing deals
biospace
26d
STAT+: Alnylam says Huntington’s drug shows promise in early study
stat
27d
GSK, Ionis hepatitis B functional cure breaks open market for followers
biospace
27d
STAT+: What to expect from the Moderna-Merck cancer vaccine data reveal
stat
27d
Why investors are taking another look at kidney disease
biospace
28d
Roche’s CEO has ‘absolutely not’ changed tune on Poseida despite scrapping CAR-T from the buyout
fiercebiotech
28d
As H-1B visa changes keep coming, biopharmas adjust hiring approach
biospace
28d
Disc’s redemption, China’s rise, Veradermics’ validation, ESMO’s headliners
biospace
28d
STAT+: Mark Cuban wants to crack open the market for rare disease treatments
stat
29d
China’s licensing deals soar as US biotechs enjoy a bumper M&A year
biospace
29d
Lilly puts $1.1B on the line for Hong Kong biotech’s AI drug delivery platform
biospace
Oct 19, 26
Merck KGaA bets on RNAi with $1.3B Silence buyout
biopharma dive
Oct 19, 26
China tightens grip on biotech platform ownership but foreign licensing deals still okay
biospace
Oct 19, 26
Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study
biopharma dive
Oct 19, 26
From strategy to scale: How Saudi Arabia is building a biotech ecosystem
biopharma dive
Oct 16, 26
Estuary sails into kidney disease space with $103M for gene therapies
biospace
Oct 16, 26
China looks to ban foreign acquisitions of critical biopharma platforms
fiercebiotech
Oct 16, 26
Estuary debuts with $103M to develop kidney disease gene therapies
endpoints
Oct 16, 26
Biogen-backed Estuary nabs $93M for kidney disease gene therapy
biopharma dive
Oct 15, 26
Belgian startup revives Galapagos CAR-T research
biopharma dive
Oct 15, 26
FDA's latest rare disease framework seeks to prioritize consistency in flexibility
biospace
Oct 15, 26
STAT+: On Wall Street, there’s trouble stirring for biotech
stat
Oct 15, 26
Estuary flows out of stealth with $103M to propel kidney disease gene therapies into clinic
fiercebiotech
Oct 15, 26
Rebranded Galapagos finally finds buyer for unwanted cell therapy pipeline
fiercebiotech
Oct 13, 26
Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earnings
biospace
Oct 12, 26
Parkinson’s cell therapy developer files to go public
biopharma dive
Oct 12, 26
Successful CDMO partnerships hinge on honest—and sometimes critical—support
biospace
← prev
page 5 of 18
next →